WOCKPHARMA — Wockhardt Share Price
- IN₹151.98bn
- IN₹173.28bn
- IN₹27.98bn
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 4.52 | ||
Price to Tang. Book | 14.27 | ||
Price to Free Cashflow | 5,066.09 | ||
Price to Sales | 5.25 | ||
EV to EBITDA | 103.76 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -1.13% | ||
Return on Equity | -10.22% | ||
Operating Margin | -1.9% |
Financial Summary
Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | IN₹m | 28,439.9 | 27,083 | 32,300 | 26,510 | 27,980 | n/a | n/a | -4.73% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Wockhardt Limited is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It manufactures a range of dosage forms, including sterile injectables and lyophilized products. The Company offers products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy and diabetology. The Company’s products across India includes Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. It has manufacturing and research facilities in India, United States of America and the United Kingdom and a manufacturing facility in Ireland.
Directors
- Habil Fakhruddin Khorakiwala CHM (77)
- Debashis Dey CCO
- Murtaza Habil Khorakiwala MDR
- Huzaifa Habil Khorakiwala EDR
- Rima Marphatia DRC
- Zahabiya Habil Khorakiwala NED
- Sanjaya Baru NID
- Davinder Brar NID
- Akhilesh Gupta NID
- Vinesh Jairath NID
- Aman Mehta NID (75)
- Tasneem Mehta NID (66)
- Last Annual
- March 31st, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- July 8th, 1999
- Public Since
- February 25th, 1994
- No. of Shareholders
- 150,292
- No. of Employees
- 2,394
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 153,409,546
- Address
- Wockhardt Towers, MUMBAI, 400051
- Web
- http://www.wockhardt.com/
- Phone
- +91 2226534444
- Auditors
- BSR & Co. LLP
Upcoming Events for WOCKPHARMA
Q3 2025 Wockhardt Ltd Earnings Release
Similar to WOCKPHARMA
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 24:37 UTC, shares in Wockhardt are trading at IN₹990.70. This share price information is delayed by 15 minutes.
Shares in Wockhardt last closed at IN₹990.70 and the price had moved by +301.42% over the past 365 days. In terms of relative price strength the Wockhardt share price has outperformed the S&P BSE 100 Index by +207.49% over the past year.
There is no consensus recommendation for this security.
Find out moreWockhardt does not currently pay a dividend.
Wockhardt does not currently pay a dividend.
Wockhardt does not currently pay a dividend.
To buy shares in Wockhardt you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹990.70, shares in Wockhardt had a market capitalisation of IN₹151.98bn.
Here are the trading details for Wockhardt:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: WOCKPHARMA
Based on an overall assessment of its quality, value and momentum Wockhardt is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Wockhardt. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +52.82%.
As of the last closing price of IN₹990.70, shares in Wockhardt were trading +58.2% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Wockhardt PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹990.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Wockhardt's management team is headed by:
- Habil Fakhruddin Khorakiwala - CHM
- Debashis Dey - CCO
- Murtaza Habil Khorakiwala - MDR
- Huzaifa Habil Khorakiwala - EDR
- Rima Marphatia - DRC
- Zahabiya Habil Khorakiwala - NED
- Sanjaya Baru - NID
- Davinder Brar - NID
- Akhilesh Gupta - NID
- Vinesh Jairath - NID
- Aman Mehta - NID
- Tasneem Mehta - NID